Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Prague, Cechia, 140 59
- Xentria Investigative Site
-
-
-
-
-
Aalborg, Danimarca, 9000
- Xentria Investigative Site
-
Aarhus, Danimarca, 8200
- Xentria Investigative Site
-
Odense, Danimarca, 5000
- Xentria Investigative Site
-
Roskilde, Danimarca, 4000
- Xentria Investigative Site
-
Vejle, Danimarca, 7100
- Xentria Investigative Site
-
-
-
-
-
Bielsk Podlaski, Polonia, 15-044
- Xentria Investigative Site
-
Lodz, Polonia, 90-153
- Xentria Investigative Site
-
-
-
-
England
-
Coventry, England, Regno Unito, CV22DX
- University Hospitals Coventry and Warwickshire NHS Trust
-
London, England, Regno Unito, SE59RS
- King's College Hospital NHS Foundation Trust
-
London, England, Regno Unito, NW12PG
- University College London Hospitals NHS Foundation Trust
-
Norwich, England, Regno Unito, NR47UY
- Norfolk and Norwich University Hospitals NHS Foundation Trust
-
Oxford, England, Regno Unito, OX37LE
- Oxford University Hospitals NHS Foundation Trust
-
-
Scotland
-
Perth, Scotland, Regno Unito, PH11NX
- NHS Tayside
-
-
-
-
-
Barcelona, Spagna, 08035
- Xentria Investigative Site
-
Barcelona, Spagna, 08036
- Xentria Investigative Site
-
Seville, Spagna, 41013
- Xentria Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Xentria Investigative Site
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80206
- Xentria Investigative Site
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32209
- Xentria Investigative Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Xentria Investigative Site
-
Chicago, Illinois, Stati Uniti, 60612
- Xentria Investigative Site
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Xentria Investigative Site
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Xentria Investigative Site
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Xentria Investigative Site
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Xentria Investigative Site
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Xentria Investigative Site
-
New York, New York, Stati Uniti, 10029
- Xentria Investigative Site
-
-
North Carolina
-
Greenville, North Carolina, Stati Uniti, 27858
- Xentria Investigative Site
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45267
- Xentria Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19140
- Xentria Investigative Site
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Xentria Investigative Site
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- Xentria Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participant between 18 to 80 years (inclusive) of age.
- Weighs between 45 kg and 160 kg (99 to 353 lbs) at Screening.
- Diagnosis of pulmonary sarcoidosis (at least 6 months before Screening) using the 2020 American Thoracic Society (ATS) Clinical Practice Guideline (Crouser et al, 2020), the European Respiratory Society (ERS) or the WASOG criteria including a compatible clinical and radiologic presentation with other causes of granulomatous disease ruled out (cutaneous and ocular involvement permitted).
- Modified Medical Research Conference (mMRC) Dyspnea Scale of ≥ 1.
- Receiving treatment of 7.5 to 25 mg/day of oral prednisone, or equivalent, during the screening period and, at the determination of the investigator, is capable of undergoing the protocol specific corticosteroid taper regimen.
- Receiving treatment with methotrexate, azathioprine, mycophenolate, leflunomide, chloroquine, or hydroxychloroquine for at least 3 months before Screening that has been at a stable dose for 4 weeks before Screening. All efforts should be made to maintain stable background therapy at the Screening dose through the intervention period at the Investigator's discretion.
- Willing to refrain from consumption of grapefruit or grapefruit juice [pomelos, exotic citrus fruits, or grapefruit hybrids] from screening visit until after the final dose.
- Polymerase chain reaction (PCR) test or rapid antigen test negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening.
- Able to provide written informed consent.
- In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements
Exclusion Criteria:
-
Pregnant or breastfeeding women or women who are planning to become pregnant during the study.
-
Participants > 65 years of age. (This exclusion criterion is only applicable for EU).
-
Known potentially significant fibrotic disease and/or active inflammation contained solely in the hilar region as shown by high-resolution computed tomography (HRCT), confirmed by a central reader. Participants with current active inflammation in the hilar region with concurrent inflammation outside the hilar region may be included.
A historical HRCT performed within 6 months of screening may be submitted for diagnostic confirmation by central review. If a subject's last HRCT was from > 6 months of screening, an HRCT should be performed during screening for diagnostic confirmation by central review.
-
Any prior TNFα inhibitor therapy.
-
Clinically significant extra-pulmonary sarcoidosis requiring systemic therapy as determined by the investigator.
-
Baseline percent predicted forced vital capacity (FVC) of < 50%.
-
Prior treatment with rituximab or repository corticotropin injection within the previous 12 months.
-
Clinically significant Central Nervous System (CNS) sarcoidosis requiring therapy, except history of isolated seventh cranial nerve palsy or evidence of demyelinating neurologic disease.
-
Advanced congestive heart failure (New York Heart Association [NYHA] 3 or 4).
-
Current disease presentation consistent with Lofgren's syndrome (i.e., presence of the triad of erythema nodosum, bilateral hilar lymphadenopathy on chest X-ray, and joint pain).
-
Clinically significant pulmonary hypertension requiring treatment. Note: Clinically significant pulmonary hypertension requiring treatment would be defined as treatment with, i.e., prostacyclins, phosphodiesterase 5 inhibitors, and endothelin receptor antagonists.
-
Known hypersensitivity to any component of the formulation of XTMAB-16.
-
Live or messenger ribonucleic acid (mRNA) vaccination within 2 weeks before Day 1 or inoculation with a live or mRNA vaccine is planned during study participation.
-
Evidence of active or latent TB by interferon-gamma release assay (IGRA) or invasive fungal infections at Screening.
-
Known positive history of malignancy other than non-melanomatous skin cancer in the last 2 years, including in-situ carcinoma of the uterine cervix completely cured by radical surgery.
-
Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, coronavirus disease (COVID-19), TB, or a known history of human immunodeficiency virus (HIV) infection at Screening.
-
Women of childbearing potential who are sexually active with a non-sterilized male partner and are not willing to adhere to highly effective birth control measures from the time of signing the informed consent, throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since the last dose of study drug.
-
Male participants who are non-sterilized and sexually active with a female partner of childbearing potential and are not willing to use highly effective contraception from the time of signing the informed consent throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since last dose of study drug.
-
Clinically significant hepatic or renal disease, including uncontrolled diabetes at the discretion of the investigator.
-
Any severe prior reaction to any type of biologics or human blood product such as albumin, IgG, etc.
-
Concurrent emphysema.
-
Known hypercalcemia due to non-sarcoidosis conditions such as untreated hyperparathyroidism, at the discretion of the investigator.
-
Abnormal ECG: ventricular arrhythmias (non-sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions, bundle branch block, axis deviation, or abnormal Q waves). In the case of a QTcF (corrected QT interval by Fredericia) interval > 450 ms (men) or > 480 ms (women; participants with bundle branch block) or PR interval outside the range of 120 to 220 ms, the assessment may be repeated once for eligibility determination at Screening or Baseline.
-
Donation or loss of 450 mL or more of his or her blood volume (including plasmapheresis) or transfusion of any blood product within 90 days prior to dosing.
-
Known uncontrolled hypertension. Note: Uncontrolled hypertension is noted as blood pressure ≥ 160/100 mmHg despite antihypertensive therapy within 3 months of randomization.
-
Clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, fatigue, new smell or taste disorder or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening.
-
In the opinion of the investigator, inability to tolerate corticosteroid taper.
-
Concurrent systemic steroid use for non-sarcoidosis conditions.
-
Concurrent known auto-immune disease requiring treatment.
-
Participation in another clinical trial of an investigational agent within 3 months (small molecule) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer.
-
Any condition that required hospitalization within the 3 months prior to Day 1 or is likely to require so during the study.
-
Clinically significant abnormalities in the Screening physical exam, medical history, vital signs, ECG, or clinical laboratory tests that are not known to be due to concurrent sarcoidosis, and in the opinion of the Investigator and Medical Monitor should preclude the participant's participation in the clinical study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Parte A - XTMAB-16: 2 mg/kg ogni 4 settimane (Q4W) per 12 settimane o Placebo
|
Infusion |
|
Sperimentale: Parte A - XTMAB-16: 4 mg/kg ogni 4 settimane (Q4W) per 12 settimane o Placebo
|
Infusion |
|
Sperimentale: Parte A - XTMAB-16: 2 mg/kg ogni 2 settimane (Q2W) per 12 settimane o Placebo
|
Infusion |
|
Sperimentale: Parte A - XTMAB-16: 4 mg/kg ogni 2 settimane (Q2W) per 12 settimane o Placebo
|
Infusion |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs), and Adverse Events of Special Interests (AESIs) throughout the study duration
Lasso di tempo: Throughout Study Duration, 20 weeks
|
To evaluate the safety and tolerability of multiple ascending doses of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Throughout Study Duration, 20 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pharmacokinetic (PK) profile including trough concentration (Ctrough)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Pharmacokinetic (PK) profile including maximum concentration (Cmax)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Pharmacokinetic (PK) profile including average concentration (Caverage)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Pharmacokinetic (PK) profile including area under the curve (AUC)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Dose normalized maximum serum concentration (Cmax/D)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Dose normalized area under the concentration time curve over the dosing interval (AUCtau/D)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Dose normalized area under the concentration time curve from time 0 to the time of the last quantifiable concentration observed (AUClast/D)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Dose normalized area under the concentration time curve from time 0 extrapolated to infinity (AUCinf/D)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Pharmacodynamics (PD) markers, including: Angiotensin converting enzyme (ACE), Soluble IL-2 receptor (sIL 2R), C-reactive protein (CRP), Interleukin-1b (IL-1b) and Calcitriol (vitamin D 1, 25)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Occurrence and persistence of anti-drug antibodies (ADA)
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Mean percent change in forced vital capacity (FVC)%
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Change in King's Sarcoidosis Questionnaire (KSQ) - Lung Score
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
The King's Sarcoidosis Questionnaire (KSQ) - General Health. Results are given as a number between 1 to 100 with higher numbers indicating better health. The minimal clinically important difference (MCID) for KSQ remains unclear in sarcoidosis.
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
The Leicester Cough Questionnaire items are scored on a 7-point Likert scale. A total score (range 3 to 21) is also calculated by adding the domain scores together, with higher scores indicating better quality of life. The MCID for chronic cough is 1.3.
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
The Steroid Toxicity Questionnaire (STQ) is a simple 12 question tool used to characterize the toxicity associated with steroid use using a 4-point scale. The MCID remains unclear in sarcoidosis. Higher scores indicate greater steroid toxicity
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Observed dose limiting toxicities (DLT), rate of adverse events of special interest (AESI) throughout the study duration between dose levels and frequencies
Lasso di tempo: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Proportion of participants who achieve the targeted tapered dose of corticosteroid
Lasso di tempo: Baseline to Week 12
|
To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use |
Baseline to Week 12
|
|
Proportion of participants who achieve at least 50% reduction in dose of corticosteroid by Week 12
Lasso di tempo: Baseline to Week 12
|
To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use |
Baseline to Week 12
|
|
Total (systemic) clearance after intravenous (IV) dose in the intended participant population
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Volume of distribution after intravenous (IV) dose and an estimate of the volume of distribution at steady state based on single dose IV data parameters in the intended participant population
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Terminal elimination phase half-life expressed in time units in the intended participant population
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Accumulation ratio repeat dosing
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Area under the effect-time curve from time 0 (predose) to the last quantifiable effect -concentration time point, t (AUEC0-t)
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Maximum observed effect (Emax, obs)
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Time to reach Emax, obs (tEmax, obs)
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Absolute and percent change in biomarkers from Baseline to End of Infusion (EOI), Interleukin-6 (IL-6) and Soluble Tumor Necrosis Factor α (sTNFα)
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Number and percentage of participants by cohort who test positive for XTMAB-16 anti-drug antibodies (ADA) and transient & persistent positive status at follow-up assessments
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Number and percentage of participants by cohort who test positive for XTMAB-16 neutralizing antibody (nAb) and transient & persistent positive status at follow-up assessments
Lasso di tempo: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- XTMAB-16-201 Part A
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .